Immunology Investor Event
Itepekimab - Clear benefit in former smokers in COPD
Phase 2 demonstrated regardless of Type 2 status¹
Higher IL-33 gene expression in lungs of former
smokers with COPD
Itepekimab reduced exacerbations in COPD former
smokers, in Type 2 and non-"
n-Type 2 patients
IL-33 gene expression
5.
8
Current smoker (CS)
Ex-smoker (CS)
Smoking Status
1. Rabe et al. Lancet Respir Med. 2021
38 Immunology Investor Event
Annualized rate
of exacerbations
2.5
2
1.5
0.5
1
42.5% RRR
39.5% RRR
53.1% RRR
3
0
Overall
<250
Itepekimab is under investigation and not yet approved by any regulatory agency. Itepekimab was generally well tolerated. Treatment emergent adverse events occurred in 78% of itepekimab patients and 80% of placebo patients.
>=250
Blood eosinophil count (cells/μl)
Placebo
■Itepekimab
sanofiView entire presentation